Evofem Biosciences Inc EVFM shares are trading lower by 59.76% at $0.44 after the company announced the pricing of a roughly $26.6 million public offering.
Evofem says the company intends to use the net proceeds from the offering for the continuation of commercialization activities related to its commercial product, Phexxi®. The offering is expected to close on or about May 24, 2022, subject to satisfaction of customary closing conditions.
See Also: Why Nio Shares Are Rising Today
Evofem Biosciences Inc is a commercial-stage biopharmaceutical company.
According to data from Benzinga Pro, Evofem Biosciences has a 52-week high of $21.30 and a 52-week low of $0.43.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
